Skip to main content
. 2021 Jun 18;5(10):1632–1648. doi: 10.1002/hep4.1708

FIG. 4.

FIG. 4

Development of different forms of response during the 14 weeks after prospective discontinuation of TDF in the FINITE trial.( 62 ) The numbers of patients in different stages of HBV replication and ALT activity are shown. Despite a relapse in HBV replication in all of the patients and ALT flares in some of the patients, most patients entered an HBsAg‐positive chronic infection (carrier) phase (white, gray) or achieved an HBsAg loss (dark blue) during the course of the study. One third of the patients required retreatment (black).